We read with great interest the recent article by Dunn et al. on the role of interferons (IFNs) in cancer immunosurveillance and sculpting of developing tumours, which they addressed as cancer immunoediting 1 . The contribution of IFNs to the dynamic relationship between the host immune system and cancer, and their central role as coordinators of tumour-immune-system interactions is reviewed in an excellent and comprehensive way. It provides compelling evidence that IFNs indeed protect the host against tumour development. However, the authors also discuss accumulating data that show that the immune system can promote tumour growth, with an obligatory role for IFNs in this process.
. In cancer patients, accelerated tryptophan degradation and increased neopterin concentrations not only reflect disease progression, but were found to be associated with reduced survival and to correlate with levels of IFNγ in the blood 6 . Therefore, in the clinical setting, the immunosuppressive role of IFNs and biochemical pathways that are triggered by IFNs become increasingly evident in chronic-disease states 7 . Once this additional facet of IFN function is generally accepted, its role in the development of the symptoms that comprise the cancer cachexia syndrome, such as anaemia, metabolic changes, fatigue and neuropsychiatric disturbances, is obvious 4 . In addition, we recently showed that IDO expression indeed contributes to the cancer immunoediting process in humans 7 . In patients with colon carcinoma, enhanced IDO expression and increased tryptophan degradation resulted in a limitation of the antitumoural immune response and correlated with the frequency of metastases and overall survival of the patient, as well as with the number of tumour-infiltrating T cells 7 . In conclusion, the diverse function of IFNs in cancer immunity fills an important gap in understanding the pathogenesis of long-term side effects of this important cytokine, leading to impaired immune function and immunodeficiency in cancer patients.
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